AstraZeneca receives FDA approval for drug that reduces mortality risk and hospitalization in heart failure patients
BusinessWorld February 17, 2021 | 11:44 am Dapagliflozin has been approved by the Food and Drug Administration (FDA) to treat heart failure in adults with reduced ejection fraction (HFrEF) in the Philippines. The results of the trial showed that dapagliflozin adds to other guideline-recommended therapies in reducing the risk of mortality and heart failure hospitalization. It also improves symptoms in patients with HFrEF. A total of 4,744 patients 22 to 94 years of age—with a mean age of 66.3 years—were randomized for the trial. The benefit of dapagliflozin was found co...
Source: bworldonline.com